21st Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy

21st Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy
September 12-15 – Bordeaux, France 

Chairs: J. Cortes, Tim P. Hughes, D. Krause 
Co-organizers: R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, F-X. Mahon,
D. Perrotti, J. Radich, D. Réa
Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann,
P. Laneuville, G. Saglio, C. Schiffer, S. Soverini, P. Valent, R. Van Etten

The Program will include

• John Goldman Prize

• Janet Rowley Prize

• iCMLf Prize

• Keynote lectures

• Special lectures

• Oral communications selected from submitted abstracts

• Brief oral communications selected from submitted abstracts

• Workshops for non-clinical scientists

• Meet-the-Expert Sessions

• Clinical and biology manned poster walks

• 2019 Saturday Clinical symposium 

• Satellite symposia

and

• John Goldman Award

Educational Objectives: 

Upon completion of this CME activity, participants should be able to:

1. Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.

2. Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.

3. Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.

4. Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.

5. Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.

6. Assess the role of allogeneic stem cell transplantation in the management of CML.

7. Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.

8. Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.

9. Discuss patient reported outcomes and their role in the management of patients with CML.

DEADLINE FOR ABSTRACTS IS CLOSED.

To book your accommodation, please register first. Then, you will receive a link for accommodation at preferential rates.

 Please find below the names of the four hotels where ESH have preferential rates for the conference.

PALAIS DES CONGRES DE BORDEAUX,

Avenue Jean Gabriel Domergue

33300 Bordeaux, France

With the support of

Emerald Conference Partner

***********

Ruby Conference Partners

Please find below the links to register to the workshops, to the Meet the Expert sessions and also to the Fun Run.

Workshops

https://forumdideias.eventsair.com/eshcml2019/workshop

Meet the Experts

https://forumdideias.eventsair.com/eshcml2019/meetexpert

Fun Run

https://forumdideias.eventsair.com/eshcml2019/funrun

21st Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy

Bordeaux, France

September 12-15, 2019

REGISTER NOW !

Join us in Mandelieu, France for the John Goldman Conference on CML: Biology and Therapy 2020

Mandelieu, Frannce

October 2-4, 2020

Chairs: Jorge Cortes, Tim P. Hughes, Daniela S. Krause

Register Here